Viral myocarditis

Article written and reviewed by Dr Luca Moretti

Viral myocarditis is an inflammatory process of the myocardium in which a viral infection contributes to injury through direct and immune mechanisms; this definition requires greater rigor than the common clinical expression “probably viral,” used after a respiratory or gastrointestinal syndrome. A prodrome increases epidemiologic plausibility, but does not demonstrate either that the virus reached the heart or that it continues to replicate when cardiac symptoms appear.

The etiologic spectrum has changed with populations, techniques and historical periods. Enteroviruses and adenoviruses have been paradigms of cardiomyocyte cytolysis; parvovirus B19 and human herpesvirus 6 are frequently detected in myocardial tissue but may be present at low load without clear significance; influenza, HIV, herpesviruses and other agents become relevant in specific settings. SARS-CoV-2 may be associated with myocardial injury through multiple mechanisms, whereas histologically proven myocarditis remains only one of the possibilities.

The clinical diagnosis of acute myocarditis is based on presentation, biomarkers, ECG, echocardiography and CMR; attributing it to a virus requires a second level of evidence. Serology generally has low ability to identify the myocardial pathogen, whereas biopsy with molecular analysis is reserved for cases in which the result changes a relevant decision; even in tissue, detection and causality do not automatically coincide.

This caution is not terminological but therapeutic; most patients do not benefit from an empiric antiviral, and immunosuppression should not be started solely on the presumption that the virus has already disappeared. The correct model distinguishes a phase of infection, a potentially injurious immune response and an outcome of recovery or remodeling, accepting that the phases may overlap in an individual patient.

The most rigorous definition separates three levels: viral infection in the body, presence of the virus or its products in the heart, and myocarditis produced by that presence. A respiratory swab addresses the first level, myocardial PCR contributes to the second, and integration with necrosis, inflammation and the biology of the agent supports the third. Confusing these levels explains many causal attributions and many non-reproducible therapeutic proposals.

Cardiotropic capacity depends not only on the entry receptor but also on the ability of the virus to overcome innate defenses, replicate in the cell type and escape clearance. A receptor expressed in the heart does not prove that the organ is infected in practice, while high viremia does not guarantee injury if the host rapidly controls replication; experimental studies and human tissue must therefore be interpreted together.

Etiology, Pathogenesis and Pathophysiology

Viruses enter the heart through the bloodstream, bind receptors expressed by cardiomyocytes, endothelium or immune cells and use the cellular machinery to replicate. Enteroviruses such as coxsackie B can produce cytolysis and alter structural proteins; adenoviruses share some entry pathways; parvovirus B19 shows predominantly endothelial tropism; these differences make it biologically inappropriate to treat every genome as equivalent.

Innate immunity recognizes viral RNA or DNA through pattern-recognition receptors and activates interferons, cytokines, complement and natural killer cells; this response limits dissemination but increases permeability, edema and contractile depression. An inadequate response may favor a high viral load, whereas excessive activation may produce injury disproportionate to the number of infected cells.

Adaptive immunity recruits cytotoxic T lymphocytes and antibodies that eliminate infected cells and viral particles; release of cardiac antigens and molecular mimicry may, however, sustain autoreactive clones, while inadequate regulation prevents resolution. When the virus can no longer be demonstrated but inflammation persists, the therapeutic problem approaches an immune-mediated inflammatory cardiomyopathy.

Viral persistence does not have the same meaning for every agent. A small amount of parvovirus B19 DNA in a noninflamed sample may reflect endothelial latency, whereas a high load with replicative RNA and active transcription more strongly supports pathogenicity. Quantification, blood controls, nucleic acid type and tissue localization improve interpretation without turning PCR into an absolute test.

HIV promotes cardiomyopathy through viremia, immunosuppression, opportunistic infections, chronic inflammation and toxicity, with a phenotype modified by antiretroviral therapy. Influenza can produce rare fulminant myocarditis during epidemics, often in the setting of severe respiratory disease; in transplant recipients, herpesviruses and other opportunists require a strategy based on immune status and specific antiviral therapy.

Microvascular injury and endothelial dysfunction contribute to noncoronary ischemia, edema and barrier abnormalities. This mechanism helps explain different CMR patterns and the possibility of troponin elevation without extensive direct cardiomyocyte necrosis; coagulation, systemic inflammation and hypoxia can add injury during severe infections without alone constituting myocarditis.

A genetic predisposition involving desmosomal, cytoskeletal or nuclear proteins may lower the threshold for injury and turn infection into an unmasking event. Persistent dysfunction, a family history or a disproportionately arrhythmogenic phenotype justify genetic assessment; in these cases, eliminating the agent does not necessarily correct the inherited substrate.

Intense exercise during replication and inflammation increases hemodynamic stress and immune signals and, in experimental models, worsens viral load and injury. Temporary restriction therefore arises not only from fear of an arrhythmia during sport, but from the possibility of aggravating the process; its duration is individualized on the basis of clinical resolution rather than the calendar of the prodrome.

The transition from infection to autoimmunity does not occur like a switch; residual antigens, genomic fragments, damaged cells and autoreactive clones may overlap, and their importance varies among sites within the same heart. Duration of symptoms is only an imperfect indicator; molecular quantification, replicative forms and immunohistochemistry provide a reconstruction closer to the mechanism when the therapeutic decision requires it.

Inflammation also alters metabolism and excitation-contraction coupling before major cell loss occurs, creating a window of recoverability that is particularly relevant in fulminant disease. If perfusion and oxygenation are supported during this phase, severely depressed function may recover; when necrosis and fibrosis predominate, the same hemodynamic therapy preserves organs but does not rebuild the myocardium.

Clinical Manifestations

The infarct-like form is common in young adults: chest pain, elevated troponin and ST-T abnormalities occur with unobstructed coronary arteries, often after fever, sore throat or diarrhea. The pain may include a pericardial component and improve when leaning forward, but myocardial involvement is defined by biomarkers and imaging; hemodynamic stability and preserved function generally identify lower, not absent, risk.

The heart-failure presentation includes dyspnea, orthopnea, congestion and low output; the fulminant form progresses rapidly with hypotension, lactate elevation, biventricular dysfunction and need for support, whereas the nonfulminant form may progressively dilate the ventricle. The rate of progression and initial response provide more useful prognostic information than the name of the presumed virus.

Palpitations, ectopy, ventricular tachycardia, blocks and syncope define the arrhythmic phenotype; risk depends on activity and scar and may persist after troponin normalization. A sustained arrhythmia or advanced block requires exclusion of aggressive histotypes, sarcoidosis and nonviral causes by biopsy when indicated.

Systemic symptoms do not predict cardiac severity; a mild respiratory infection may precede severe myocarditis, whereas severe pneumonia may produce troponin elevation through hypoxia, sepsis and overload without myocardial infiltration. Diagnosis must demonstrate a myocarditis phenotype and not use the biomarker as a synonym.

In children and infants, irritability, reduced feeding, tachypnea, pallor and tachycardia may replace pain. Neonatal enterovirus infection may be disseminated and extremely severe, with coagulopathy and hepatitis; suspicion must integrate perinatal epidemiology and requires advanced pediatric care.

In immunocompromised patients, a high viral load may produce systemic disease while the infiltrate is scant. By contrast, immune reconstitution may amplify inflammatory manifestations; biopsy, blood viral loads and treatment history must be interpreted together to decide whether to reduce immunosuppression, use antivirals or control the response.

A chronic form presents with exercise intolerance, dilated cardiomyopathy and arrhythmias months after the initial episode, but contemporaneous virologic documentation is often lacking. At this stage, labeling the disease “viral” on the basis of a remote cold adds false certainty; tissue, genetics and the course under standard therapy help reconstruct a plausible mechanism.

A viral history is reconstructed with date, site, test performed, severity and symptom-free interval, avoiding generic formulations such as recent influenza. Absence of fever does not necessarily reduce suspicion, whereas high fever during severe pneumonia increases the probability of multifactorial injury rather than cardiac invasion. Precise history-taking is especially useful for selecting samples that remain informative within the correct biological window.

Troponin is interpreted as a dynamic marker of injury and not as a direct measure of viral load, because it may decrease while function worsens or rise in a hemodynamically stable patient. Natriuretic peptides, lactate, right ventricular function and arrhythmias describe different dimensions; their combination makes it possible to recognize a high-risk phenotype even when a single value does not appear extreme.

Investigations and Diagnosis

ECG and telemetry characterize ST-T abnormalities, blocks and arrhythmias; troponin and natriuretic peptides measure injury and stress without identifying the cause. Complete blood count, C-reactive protein, renal and liver function, and electrolytes define severity and alternatives; a positive respiratory swab proves a respiratory tract infection, not necessarily the presence of the same virus in the heart.

Echocardiography assesses biventricular function, wall thickness and edema, effusion, strain and hemodynamic profile; regional abnormalities may mimic ischemia, whereas normal function does not exclude a focally arrhythmogenic process. Serial examinations are important because the trajectory may change more rapidly than the initial image.

CMR applies criteria based on edema and nonischemic injury using T2, T1, extracellular volume and LGE. The inferolateral subepicardial pattern is classic but not universal and does not identify an agent; timing, quality and treatment affect sensitivity, and a negative examination does not close a high-risk case.

Routine viral serology is not recommended for assigning causality because antibodies are common in the population and concordance with tissue is poor. It is useful for infections in which serologic status changes systemic management, such as HIV or hepatitis, or in specific protocols; isolated IgM requires confirmation and temporal interpretation.

Biopsy with molecular diagnostics is performed in high-risk or unresolved phenotypes and requires multiple properly preserved fragments. Histology and immunohistochemistry define inflammation and necrosis, whereas quantitative PCR and methods assessing replication characterize the agent; blood collected at the same time helps identify viremia or blood contamination of the sample.

A positive PCR is interpreted through viral load, species, cellular site, transcriptional activity and concordance with injury; a negative PCR may reflect focal sampling, clearance of the virus before the immune phase or true absence. Neither a positive nor a negative result alone justifies treatment without a mechanism and therapeutic evidence.

Coronary angiography or CT angiography excludes coronary disease when required by the presentation; blood cultures, testing for Borrelia, HIV and other investigations respond to clinical data, not indiscriminate panels. The differential diagnosis includes Takotsubo syndrome, ischemic MINOCA, pulmonary embolism, sepsis and genetic cardiomyopathies.

In biopsy specimens, quantification is interpreted in relation to tissue quality and quantity and, when possible, to concomitant viremia. Hybridization or cellular localization techniques may distinguish an endothelial signal from a cardiomyocyte signal, while detection of replicative RNA increases the plausibility of activity. These investigations are not necessary in mild disease that recovers, but become proportionate when prolonged immune treatment is being considered.

CMR may be limited by tachycardia, devices, renal failure or instability and must not delay biopsy and support in a critically ill patient. In stable cases, timing and sequences are optimized to acquire mapping before edema and corticosteroids reduce sensitivity; a technically incomplete examination is described as such, rather than translated into absence of myocarditis.

Treatment and Prognosis

Treatment of most acute forms in immunocompetent patients is cardiologic and supportive. Congestion and dysfunction receive heart-failure therapy adapted to the phase, whereas shock and hypoperfusion require intensive care and early mechanical support if the trajectory worsens. Drugs that depress hemodynamics are avoided during instability and introduced after restoration of perfusion.

There is no universal antiviral for myocarditis; oseltamivir treats influenza according to infectious-disease indications and antiretrovirals control HIV, whereas acyclovir or ganciclovir have specific targets in appropriate patients; none of these regimens can be transferred to a different virus. Interferons and immunoglobulins have limited or context-specific evidence and are not used indiscriminately as routine therapy.

Immunosuppression is indicated in specific histotypes and may be considered in virus-negative lymphocytic forms, unstable or persistent, after specialist assessment. In the presence of documented viral replication, the risk-benefit ratio changes and depends on the agent; biopsy is therefore a potential therapeutic tool, not merely a histologic formality.

Arrhythmias and blocks are treated according to severity, taking reversibility into account; temporary devices provide protection during the acute phase, whereas a permanent ICD depends on cardiac arrest, tachycardia, function, scar and recovery. Ablation during active inflammation may have high recurrence rates and is reserved for situations in which electrical control cannot wait.

Suspension of intense sports activity provides protection during the vulnerable period; return requires absence of symptoms, stable biomarkers, functional recovery and rhythm assessment, with CMR selected according to severity and guidelines. A negative swab is not the criterion for cardiac recovery.

The prognosis of uncomplicated infarct-like forms with preserved function is often favorable, although residual LGE requires follow-up. Shock, biventricular dysfunction, sustained arrhythmias, advanced block, extensive LGE and lack of early recovery identify greater risk; fulminant disease may recover substantially if the patient survives the critical phase with organs protected.

During follow-up, symptoms, ECG, Holter monitoring, echocardiography and biomarkers define recovery, whereas CMR measures edema and scar when useful. Persistent dysfunction prompts assessment for inflammatory and genetic cardiomyopathy; repeating serologic panels does not document myocardial recovery and rarely adds information.

Discharge does not conclude the decision-making phase because function may improve before electrical stabilization and LGE may persist after edema. The program specifies timing of ECG, echocardiography, monitoring and exercise reassessment, distinguishing the patient with preserved function from the survivor of shock or tachycardia. A generic recommendation to rest without return criteria produces immobility and anxiety or an excessively early resumption.

Standard heart-failure therapy is not automatically discontinued after initial recovery because remodeling may continue and overly rapid reduction makes it difficult to distinguish relapse from loss of neurohormonal protection. Duration and de-escalation are individualized according to function, symptoms and risk; in patients with genetic predisposition, maintenance assumes even greater importance even when the infection is remote.

Complications

Cardiogenic shock may cause renal, hepatic and neurologic failure before the immune response subsides; ECMO or ventricular assist devices can provide a bridge to recovery or transplantation, but entail bleeding, ischemia, infections and thrombosis. Selection and timing require a team capable of modifying the strategy according to the function of both ventricles.

Ventricular arrhythmias and sudden death may occur during acute edema or in the late scar. Normalization of ejection fraction reduces but does not eliminate risk if extensive LGE or a history of tachycardia persists; monitoring and device decisions must therefore go beyond simple echocardiographic follow-up.

Progression to dilated cardiomyopathy combines cell loss, fibrosis, autoimmunity and sometimes persistence. Comprehensive neurohormonal therapy and selected genetic investigation become central; late empiric antivirals, in the absence of evidence and an indication, expose patients to toxicity without a defined target.

Ventricular thrombi and emboli may occur with severe dysfunction or apical involvement. Contrast imaging and CMR improve detection, whereas anticoagulation follows the presence of thrombus or other indications and not the diagnosis alone; bleeding risk is particularly important during procedures and mechanical support.

Recurrences of pain and troponin elevation may reflect a new infection, immune reactivation, premature exercise or an underlying genetic diagnosis. Attributing every episode to the same virus without new evidence prevents a useful reassessment; comparative CMR and, in high-risk cases, repeat biopsy can distinguish activity from scar.

Inappropriate immunosuppression may increase replication and opportunistic infections, whereas its omission in virus-negative immune-mediated myocarditis may allow injury to progress. This apparent contradiction is resolved by tissue and clinical characterization, not by a single rule; prophylaxis and monitoring follow the type and duration of the agents used.

The psychological consequences of cardiac arrest, shock and sports restriction include anxiety, fear of exertion and difficulty returning to daily life. Precise communication about the limits of virologic evidence avoids both fears of contagion and minimization; rehabilitation and psychological support complete recovery in complex cases.

Prevention cannot rely on generic “immune boosting,” but uses available vaccinations, hygiene, treatment of specific infections and protection of immunocompromised patients according to risk. A vaccine reduces the disease caused by its own agent and does not prevent all myocarditis, while an event temporally following vaccination must be assessed with the same clinical criteria without confusing association and causality; balanced information protects against both fear and false reassurance.

In counseling, the word viral is presented as a hypothesis with a level of evidence, not as a permanently contagious condition. After systemic infection has ended, family members and colleagues are not exposed by the scar or residual cardiomyopathy. This distinction allows the patient to focus on rhythm, therapy and recovery, avoiding repeated serologic tests and isolation measures with no utility.

Future research will need to distinguish active replication, innocuous persistence and autonomous inflammation more effectively through transcriptomics, cellular localization and tissue-stratified therapeutic studies. Grouping patients only on the basis of CMR dilutes opposing effects and contributes to inconclusive results. In current practice, recognizing these limitations avoids promises about antivirals or immunotherapies and supports referral of complex phenotypes to centers with advanced diagnostics.